BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Glactiv sitagliptin regulatory update

In May, Japan approved Glactiv sitagliptin to treat Type II diabetes in combination with alpha-glucosidase inhibitors. The dipeptidyl peptidase-4 (DPP-4) inhibitor is already marketed in Japan to treat Type...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >